

- Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. *Mayo Clin Proc* 2010;85:838–854.
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. *N Engl J Med* 2003;349:1543–1554.
- Honorat J, Antoine JC. Paraneoplastic neurological syndromes. *Orphanet J Rare Dis* 2007;2:22.
- de Beukelaar JW, Sillevius Smitt PA. Managing paraneoplastic neurological disorders. *Oncologist* 2006;11:292–305.
- Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. *Neurology* 2011;77:179–189.
- Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. *Ann Neurol* 2000;47:9–17.
- Antoine JC, Camdessanche JP. Treatment options in paraneoplastic disorders of the peripheral nervous system. *Curr Treat Options Neurol* 2013;15:210–223.
- Psimaras D, Carpentier AF, Rossi C, et al. Cerebrospinal fluid study in paraneoplastic syndromes. *J Neurol Neurosurg Psychiatry* 2010;81:42–45.
- Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *J Neurol Neurosurg Psychiatry* 2004;75:1135–1140.
- Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. *Ann Indian Acad Neurol* 2012;15:6–12.
- Wright CE, Angus JA. Effects of N-, P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission. *Br J Pharmacol* 1996;119:49–56.
- Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. *Physiol Rev* 2003;83:117–161.
- Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. *N Engl J Med* 1995;332:1467–1474.
- Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. *Neurology* 2003;60:230–234.
- Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. *Neurology* 2004;63:282–286.
- Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. *Brain* 2003;126:1409–1418.
- Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. *Brain* 1997;120:1279–1300.
- Battaller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. *Brain* 2001;124:437–443.
- Hassan KA, Kalemkerian GP, Trobe JD. Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer. *J Neuroophthalmol* 2008;28:27–30.
- DiBaise JK. Paraneoplastic gastrointestinal dysmotility: when to consider and how to diagnose. *Gastroenterol Clin North Am* 2011;40:777–786.
- Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. *Gastroenterology* 1991;100:137–142.
- Lee HR, Lennon VA, Camilleri M, et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. *Am J Gastroenterol* 2001;96:373–379.
- Zsimopoulou P, Brenner T, Trakas N, et al. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. *Autoimmun Rev* 2013;12:924–930.
- Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. *Neurology* 2002;59:1844–1850.
- Rosenberg M, Jauregui WO, De Vega ME, et al. Recurrence of thymic hyperplasia after thymectomy in myasthenia gravis. Its importance as a cause of failure of surgical treatment. *Am J Med* 1983;74:78–82.
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol* 2013;12:157–165.
- Wirtz PW, Sotodeh M, Nijhuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. *J Neurol Neurosurg Psychiatry* 2002;73:766–768.
- Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. *Muscle Nerve* 2005;32:515–520.
- Voltz R. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. *J Neurol* 2006;253:V33–V38.
- Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. *J Pediatr Hematol Oncol* 2006;28:585–593.
- Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. *J Neurol* 2006;253:16–20.
- Punga AR, Stalberg E. Acetylcholinesterase inhibitors in MG: to be or not to be? *Muscle Nerve* 2009;39:724–728.
- Kalia J, Swartz KJ. Elucidating the molecular basis of action of a classic drug: guanidine compounds as inhibitors of voltage-gated potassium channels. *Mol Pharmacol* 2011;80:1085–1095.
- Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. *Neurology* 2000;54:603–607.
- McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. *N Engl J Med* 1989;321:1567–1571.
- Low PA. Autonomic neuropathies. *Curr Opin Neurol* 2002;15:605–609.
- Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. *Am J Med* 2007;120:841–847.
- Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as palliative treatment for chronic colonic pseudo-obstruction in a patient with autonomic paraneoplastic neuropathy. *Am J Gastroenterol* 2003;98:708–709.
- Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. *J Clin Oncol* 1997;15:2866–2872.
- Greenberg A, Verbalis JG. Vasopressin receptor antagonists. *Kidney Int* 2006;69:2124–2130.
- Lehrich RW, Ortiz-Melo DI, Patel MB, et al. Role of vaptans in the management of hyponatremia. *Am J Kidney Dis* 2013;62:364–376.
- Rafopoulos H. Diagnosis and management of hyponatremia in cancer patients. *Support Care Cancer* 2007;15:1341–1347.
- List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. *J Clin Oncol* 1986;4:1191–1198.
- Talmi YP, Hoffman HT, McCabe BF. Syndrome of inappropriate secretion of arginine vasopressin in patients with cancer of the head and neck. *Ann Otol Rhinol Laryngol* 1992;101:946–949.
- Ferlito A, Rinaldo A, Devaney KO. Syndrome of inappropriate antidiuretic hormone secretion associated with head neck cancers: review of the literature. *Ann Otol Rhinol Laryngol* 1997;106:878–883.
- Lee BW, Ihm SH, Shin HS, et al. Malignant thymoma associated with myasthenia gravis, Graves' disease, and SIADH. *Intern Med* 2008;47:1009–1012.
- Galesic K, Krizanac S, Vrkljan M, et al. Syndrome of inappropriate secretion of antidiuretic hormone due to malignant thymoma. *Nephron* 2002;91:752–754.
- Eliakim R, Vertman E, Shinhar E. Syndrome of inappropriate secretion of antidiuretic hormone in Hodgkin's disease. *Am J Med Sci* 1986;291:126–127.
- Kobayashi K, Yokote T, Akioka T, et al. Inappropriate antidiuretic hormone production in diffuse large B-cell lymphoma. *Br J Haematol* 2008;143:2.
- Hirata Y, Yokote T, Nishiwaki U, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with primary cutaneous anaplastic large cell lymphoma. *Br J Haematol* 2012;157:412.
- Nagashima Y, Iino K, Oki Y, et al. A rare case of ectopic antidiuretic hormone-producing pancreatic adenocarcinoma: new diagnostic approach. *Intern Med* 1996;35:280–284.
- Garzotto M, Beer TM. Syndrome of inappropriate antidiuretic hormone secretion: a rare complication of prostate cancer. *J Urol* 2001;166:1386.
- Yamazaki T, Suzuki H, Tobe T, et al. Prostate adenocarcinoma producing syndrome of inappropriate secretion of antidiuretic hormone. *Int J Urol* 2001;8:513–516.
- Gasparini ME, Broderick GA, Narayan P. The syndrome of inappropriate antidiuretic hormone secretion in a patient with adenocarcinoma of the prostate. *J Urol* 1993;150:978–980.
- Adrogue HJ, Madias NE. Hyponatremia. *N Engl J Med* 2000;342:1581–1589.
- Arief AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. *Medicine* 1976;55:121–129.
- Gross P, Reimann D, Neidel J, et al. The treatment of severe hyponatremia. *Kidney Int Suppl* 1998;64:S6–S11.
- Cullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. *Ann Rev Med* 1993;44:289–301.
- Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. *Am J Med* 2006;119:71.e1–e8.
- Schwartz WB, Bennett W, Curelop S, et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. *Am J Med* 1957;23:529–542.
- Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. *Am J Med* 1967;42:790–806.
- Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med* 2007;356:2064–2072.
- Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. *N Engl J Med* 2005;352:1884–1890.
- Decaux G, Brimiouille S, Genette F, et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. *Am J Med* 1980;69:99–106.
- Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. *Br Med J* 1981;283:1081–1083.

66. Decaux G, Unger J, Brimiouille S, et al. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. *JAMA* 1982;247:471-474.
67. Decaux G. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. *Nephron* 1983;35:82-828.
68. Cherrill DA, Stole RM, Birge JR, et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. *Ann Intern Med* 1975;83:654-656.
69. Forrest JN Jr, Cox M, Hong C, et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. *N Engl J Med* 1978;298:173-177.
70. Perks WH, Walters EH, Tams IP, et al. Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. *Thorax* 1979;34:324-327.
71. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. *JAMA* 1980;243:2513-2515.
72. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. *Nat Rev Nephrol* 2009;5:270-276.
73. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. *Am J Med* 2007;120:S1-S21.
74. Macion-Dazar R, Callahan N, Xu Z, et al. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. *J Pharmacol Exp Ther* 2006;316:564-571.
75. Peri A. Clinical review: the use of vaptans in clinical endocrinology. *J Clin Endocrinol Metab* 2013;98:1321-1332.
76. Tahara A, Tomura Y, Wada KI, et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. *J Pharmacol Exp Ther* 1997;282:301-308.
77. Martinez-Castelao A. Conivaptan (Yamanouchi). *Curr Opin Invest Drugs* 2002;3:89-95.
78. Sulemanjee NZ, Schwarz ER. Conivaptan: a selective vasopressin antagonist. *Drugs Today (Barc)* 2006;42:379-386.
79. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. *J Clin Endocrinol Metab* 2006;91:2145-2152.
80. Annane D, Decaux G, Smith N, et al. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. *Am J Med Sci* 2009;337:28-36.
81. Ghali JK, Farah JO, Daifallah S, et al. Conivaptan and its role in the treatment of hyponatremia. *Drug Des Devel Ther* 2009;3:253-268.
82. Quittnat F, Gross P. Vaptans and the treatment of water-retaining disorders. *Semin Nephrol* 2006;26:234-243.
83. Ghali JK, Hamad B, Yasothan U, et al. Tolvaptan. *Nat Rev Drug Discov* 2009;8:611-612.
84. Schrier RW, Gross P, Gheorghide M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *N Engl J Med* 2006;355:2099-2112.
85. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. *Eur J Endocrinol* 2011;164:725-732.
86. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. *J Am Soc Nephrol* 2010;21:705-712.
87. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med* 2013;126:S1-S42.
88. Kleinschmidt-DeMasters BK, Norenberg MD. Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis. *Science* 1981;211:1068-1070.
89. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. *N Engl J Med* 1986;314:1535-1542.
90. Sterns RH, Cappuccino JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. *J Am Soc Nephrol* 1994;4:1522-1530.
91. King JD, Rosner MH. Osmotic demyelination syndrome. *Am J Med Sci* 2010;339:561-567.
92. Brunner JE, Redmond JM, Haggag AM, et al. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. *Ann Neurol* 1990;27:61-66.
93. Miller GM, Baker HL Jr, Okazaki H, et al. Central pontine myelinolysis and its imitators: MR findings. *Radiology* 1988;168:795-802.
94. Newell-Price J, Bertagna X, Grossman AB, et al. Cushing's syndrome. *Lancet* 2006;367:1605-1617.
95. Liddle GW, Nicholson WE, Island DP, et al. Clinical and laboratory studies of ectopic humoral syndromes. *Recent Prog Horm Res* 1969;25:283-314.
96. Aniszewski JP, Young WF Jr, Thompson GB, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. *World J Surg* 2001;25:934-940.
97. Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. *J Clin Endocrinol Metab* 2005;90:4955-4962.
98. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropic syndrome: clinical features, diagnosis, management, and long-term follow-up. *J Clin Endocrinol Metab* 2006;91:371-377.
99. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, et al. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. *Cancer* 2011;117:4381-4389.
100. Nieman LK. Diagnostic tests for Cushing's syndrome. *Ann N Y Acad Sci* 2002;970:112-118.
101. Crapo L. Cushing's syndrome: a review of diagnostic tests. *Metabolism* 1979;28:955-977.
102. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. *Ann Intern Med* 1990;112:434-444.
103. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. *J Clin Endocrinol Metab* 1998;83:2681-2686.
104. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2008;93:1526-1540.
105. Carroll T, Raff H, Findling JW. Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome. *Nat Clin Pract Endocrinol Metab* 2008;4:344-350.
106. Newell-Price J, Trainer P, Besser M, et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. *Endocr Rev* 1998;19:647-672.
107. Klose M, Kofoed-Enevoldsen A, Ostergaard Kristensen L. Single determination of plasma ACTH using an immunoradiometric assay with high detectability differentiates between ACTH-dependent and -independent Cushing's syndrome. *Scand J Clin Lab Invest* 2002;62:33-37.
108. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. *J Clin Endocrinol Metab* 2003;88:5593-5602.
109. Reimondo G, Paccotti P, Minetto M, et al. The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. *Clin Endocrinol* 2003;58:718-724.
110. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. *N Engl J Med* 1991;325:897-905.
111. Wiggam MI, Heaney AP, McIlrath EM, et al. Bilateral inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropic-dependent Cushing's syndrome: a comparison with other diagnostic tests. *J Clin Endocrinol Metab* 2000;85:1525-1532.
112. Findling JW, Kehoe ME, Shaker JL, et al. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropic (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. *J Clin Endocrinol Metab* 1991;73:408-413.
113. Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropic syndrome. *J Clin Endocrinol Metab* 1999;84:487-492.
114. Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. *Discov Med* 2012;13:171-179.
115. Engelhardt D. Steroid biosynthesis inhibitors in Cushing's syndrome. *Clin Invest* 1994;72:481-488.
116. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. *J Steroid Biochem Mol Biol* 1994;49:261-267.
117. Alexandraki KI, Grossman AB. The ectopic ACTH syndrome. *Rev Endocr Metab Disord* 2010;11:117-126.
118. Guettier JM, Gorden P. Hypoglycemia. *Endocrinol Metab Clin North Am* 2006;35:753-766, viii-ix.
119. de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. *Endocr Relat Cancer* 2007;14:979-993.
120. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2009;94:709-728.
121. Service FJ. Hypoglycemic disorders. *N Engl J Med* 1995;332:1144-1152.
122. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. *Cancer* 1998;82:1585-1592.
123. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. *Bone* 2000;27:333-338.
124. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. *Proc Natl Acad Sci U S A* 2001;98:6500-6505.
125. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. *N Engl J Med* 2003;348:1656-1663.
126. Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. *Endocr Relat Cancer* 2011;18:R53-R77.
127. Perwad F, Zhang MY, Tenenhouse HS, et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1 α -hydroxylase expression in vitro. *Am J Physiol Renal Physiol* 2007;293:F1577-F1583.

128. Jan de Beur SM. Tumor-induced osteomalacia. *JAMA* 2005;294:1260–1267.
129. Rico H, Fernandez-Miranda E, Sanz J, et al. Oncogenic osteomalacia: a new case secondary to a malignant tumor. *Bone* 1986;7:325–329.
130. Ogose A, Hotta T, Emura I, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. *Skeletal Radiol* 2001;30:99–103.
131. Halperin F, Anderson RJ, Mulder JE. Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels. *Nat Clin Pract Endocrinol Metab* 2007;3:721–725.
132. Dupond JL, Mahammed H, Prie D, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. *Bone* 2005;36:375–378.
133. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. *Am J Med* 2004;116:11S–26S.
134. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. *Med Oncol* 2008;25:12–21.
135. Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005;352:1011–1023.
136. Gangat N, Wolanskyj AP. Anemia of chronic disease. *Semin Hematol* 2013;50:232–238.
137. Spivak JL. The anemia of cancer: death by a thousand cuts. *Nat Rev Cancer* 2005;5:543–555.
138. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *J Clin Oncol* 2010;28:4996–5010.
139. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *Blood* 2010;116:4045–4059.
140. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. *Lancet* 2009;373:1532–1542.
141. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst Rev* 2012;12:CD003407.
142. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. *Blood* 2010;115:3616–3624.
143. Cooke KS, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. *Blood* 2013;122:3054–3061.
144. Hashizume M, Uchiyama Y, Horai N, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. *Rheumatol Int* 2010;30:917–923.
145. Fatih N, Camberlein E, Island ML, et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. *J Mol Med* 2010;88:477–486.
146. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. *Br J Haematol* 2008;142:505–514.
147. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. *Blood* 2002;99:1092–1094.
148. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. *Br J Haematol* 2010;148:791–796.
149. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. *Br J Haematol* 2001;114:891–898.
150. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *J Clin Oncol* 2011;29:573–582.
151. McMullin MF. The classification and diagnosis of erythrocytosis. *Int J Lab Hematol* 2008;30:447–459.
152. Kremyanskaya M, Mascarenhas J, Hoffman R. Why does my patient have erythrocytosis? *Hematol Oncol Clin North Am* 2012;26:267–283, vii–viii.
153. Nakayama K, Nakayama N, Rahman MT, et al. Uterine leiomyosarcoma producing granulocyte colony stimulating factor. *Int J Gynecol Pathol* 2012;31:172–177.
154. Hintzen RQ, Voormolen J, Sonneveld P, et al. Glioblastoma causing granulocytosis by secretion of granulocyte-colony-stimulating factor. *Neurology* 2000;54:259–261.
155. Hasegawa S, Suda T, Negi K, et al. Lung large cell carcinoma producing granulocyte-colony-stimulating factor. *Ann Thorac Surg* 2007;83:308–310.
156. Mabuchi S, Matsumoto Y, Iohashi F, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. *Gynecol Oncol* 2011;122:25–32.
157. Worley MJ Jr, Nitschmann CC, Shoni M, et al. The significance of preoperative leukocytosis in endometrial carcinoma. *Gynecol Oncol* 2012;125:561–565.
158. Mandrekar SJ, Northfelt DW, Schild SE, et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. *J Thorac Oncol* 2006;1:556–563.
159. Shoenfeld Y, Tal A, Berliner S, et al. Leukocytosis in non hematological malignancies—a possible tumor-associated marker. *J Cancer Res Clin Oncol* 1986;111:54–58.
160. Ascensao JL, Oken MM, Ewing SL, et al. Leukocytosis and large cell lung cancer. A frequent association. *Cancer* 1987;60:903–905.
161. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. *J Clin Pathol* 1981;34:1343–1348.
162. Rothenberg ME. Eosinophilia. *N Engl J Med* 1998;338:1592–1600.
163. Balian A, Bonte E, Naveau S, et al. Intratumoral production of interleukin-5 leading to paraneoplastic peripheral eosinophilia in hepatocellular carcinoma. *J Hepatol* 2001;34:355–356.
164. Pandit R, Scholnik A, Wulfekuhler L, et al. Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. *Am J Hematol* 2007;82:234–237.
165. Kato H, Kohata K, Yamamoto J, et al. Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer. *Int J Hematol* 2010;91:328–330.
166. Schafer AI. Thrombocytosis and thrombocythemia. *Blood Rev* 2001;15:159–166.
167. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. *J Intern Med* 1999;245:295–300.
168. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. *Semin Thromb Hemost* 2004;30:95–108.
169. Bambace NM, Holmes CE. The platelet contribution to cancer progression. *J Thromb Haemost* 2011;9:237–249.
170. Curth HO. Skin lesions and internal carcinomas. In: Andrade R, Gumport SL, Popkin GL, Rees D, eds. *Cancer of the skin: biology-diagnosis-management*. Philadelphia: Saunders; 1976:1308–1341.
171. Yuste-Chaves M, Unamuno-Perez P. Cutaneous alerts in systemic malignancy: part I. *Actas Dermosifiliogr* 2013;104:285–298.
172. Moore RL, Devere TS. Epidermal manifestations of internal malignancy. *Dermatol Clin* 2008;26:17–29, vii.
173. Schwartz RA, Burgess GH. Florid cutaneous papillomatosis. *Arch Dermatol* 1978;114:1803–1806.
174. Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. *Medicine* 1968;47:33–51.
175. Talsania N, Harwood CA, Piras D, et al. Paraneoplastic acanthosis nigricans: The importance of exhaustive and repeated malignancy screening. *Dermatol Online J* 2010;16:8.
176. Abreu Velez AM, Howard MS. Diagnosis and treatment of cutaneous paraneoplastic disorders. *Dermatol Ther* 2010;23:662–675.
177. Stone SP, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. *Clin Dermatol* 2005;23:301–306.
178. Caux F, Lebbe C, Thomine E, et al. Erythema gyratum repens. A case studied with immunofluorescence, immunoelectron microscopy and immunohistochemistry. *Br J Dermatol* 1994;131:102–107.
179. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. *Am J Med Sci* 2001;321:302–305.
180. Bazex A, Griffiths A. Acrokeratosis paraneoplastica—a new cutaneous marker of malignancy. *Br J Dermatol* 1980;103:301–306.
181. Bologna JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. *Medicine* 1991;70:269–280.
182. Ellis DL, Kafka SP, Chow JC, et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple achorchordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. *N Engl J Med* 1987;317:1582–1587.
183. Vabres P, Lacombe D, Rabinowitz LG, et al. The gene for Bazex-Dupre-Christol syndrome maps to chromosome Xq. *J Invest Dermatol* 1995;105:87–91.
184. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. *Arch Dermatol* 1993;129:883–886.
185. Nousari HC, Deterding R, Wojteczak H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. *N Engl J Med* 1999;340:1406–1410.
186. Amagai M, Nishikawa T, Nousari HC, et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. *J Clin Invest* 1998;102:775–782.
187. Yuste Chaves M, Unamuno Perez P. Cutaneous manifestations of systemic malignancies: part 2. *Actas Dermosifiliograf* 2013;104:543–553.
188. Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. *J Am Acad Dermatol* 2007;56:153–159.
189. Marquez G, Herrera-Acosta E, Vidal I, et al. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). *Int J Dermatol* 2009;48:97–98.
190. Roe E, Garcia Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. *J Am Acad Dermatol* 2006;55:429–437.
191. Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. *J Clin Oncol* 1988;6:1887–1897.

192. Pineda C, Martinez-Lavin M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. *Rheum Dis Clin North Am* 2013;39:383–400.
193. Hayashi M, Sekikawa A, Saijo A, et al. Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. *Anticancer Res* 2005;25:2435–2438.
194. King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. *Clin Lung Cancer* 2008;9:179–182.
195. Jayakar BA, Abelson AG, Yao Q. Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. *Semin Arthritis Rheum* 2011;41:291–296.
196. Yeo W, Leung SF, Chan AT, et al. Radiotherapy for extreme hypertrophic pulmonary osteoarthropathy associated with malignancy. *Clin Oncol* 1996;8:195–197.
197. Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. *Rheum Dis Clin North Am* 2011;37:593–606.
198. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. *Lancet* 2003;362:971–982.
199. Aggarwal R, Oddis CV. Paraneoplastic myalgias and myositis. *Rheum Dis Clin North Am* 2011;37:607–621.
200. Zahr ZA, Baer AN. Malignancy in myositis. *Curr Rheumatol Rep* 2011;13:208–215.
201. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. *Lancet* 2001;357:96–100.
202. Huang YL, Chen YJ, Lin MW, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. *Br J Dermatol* 2009;161:854–860.